RESUMO
Chest Radiography is a non-invasive imaging modality for diagnosing and managing chronic lung disorders, encompassing conditions such as pneumonia, tuberculosis, and COVID-19. While it is crucial for disease localization and severity assessment, existing computer-aided diagnosis (CAD) systems primarily focus on classification tasks, often overlooking these aspects. Additionally, prevalent approaches rely on class activation or saliency maps, providing only a rough localization. This research endeavors to address these limitations by proposing a comprehensive multi-stage framework. Initially, the framework identifies relevant lung areas by filtering out extraneous regions. Subsequently, an advanced fuzzy-based ensemble approach is employed to categorize images into specific classes. In the final stage, the framework identifies infected areas and quantifies the extent of infection in COVID-19 cases, assigning severity scores ranging from 0 to 3 based on the infection's severity. Specifically, COVID-19 images are classified into distinct severity levels, such as mild, moderate, severe, and critical, determined by the modified RALE scoring system. The study utilizes publicly available datasets, surpassing previous state-of-the-art works. Incorporating lung segmentation into the proposed ensemble-based classification approach enhances the overall classification process. This solution can be a valuable alternative for clinicians and radiologists, serving as a secondary reader for chest X-rays, reducing reporting turnaround times, aiding clinical decision-making, and alleviating the workload on hospital staff.
Assuntos
COVID-19 , Radiografia Torácica , Índice de Gravidade de Doença , Humanos , COVID-19/diagnóstico por imagem , COVID-19/diagnóstico , Radiografia Torácica/métodos , SARS-CoV-2/isolamento & purificação , Pulmão/diagnóstico por imagem , Pulmão/patologia , Diagnóstico por Computador/métodos , Tomografia Computadorizada por Raios X/métodos , AlgoritmosRESUMO
The present study involves the design, synthesis, and biological evaluation of a series of thirty-three, pyrazole-based and N,N-diethylcarbamate functionalized, novel aurone analogs, against AGS cancer cell line. These novel aurone analogs are obtained from the reaction of pyrazole-based 6-hydroxyaurones with diethyl carbamoyl chloride using mild basic reagent. The cytotoxic activities of these compounds were evaluated against a human gastric adenocarcinoma cell line (AGS) and disclosed some potential outcomes as several analogs were found to have cytotoxicity better than the reference drugs Oxaliplatin and Leucovorin. The structure-activity relationship (SAR) study further unveiled the critical role of replacing the hydroxyl group in ring A with a carbamoyl group for cytotoxic activity. Among these aurone analogs, 8e and 8f, with IC50 values of 6.5 ± 0.024 µM and 6.6 ± 0.035 µM, respectively, are identified as the most active compounds. Molecular docking studies were conducted against HER2, a human epidermal growth factor involved in gastric and ovarian cancer, to investigate the binding interactions between the compounds and the protein HER2, where7e and 8e exhibited maximum interactions.
RESUMO
Triple-negative breast cancer is characterized by high lethality attributed to factors such as chemoresistance, transcriptomic, and genomic heterogeneity, leading to a poor prognosis and limiting available targeted treatment options. While the identification of molecular targets remains pivotal for therapy involving chemo drugs, the current challenge lies in the poor response rates, low survival rates, and frequent relapses. Despite various clinical investigations exploring molecular targeted therapies in conjunction with conventional chemo treatment, the outcomes have been less than optimal. The critical need for more effective therapies underscores the urgency to discover potent novel treatments, including molecular and immune targets, as well as emerging strategies. This review provides a comprehensive analysis of conventional treatment approaches and explores emerging molecular and immune-targeted therapeutics, elucidating their mechanisms to address the existing obstacles for a more effective management of triple-negative breast cancer.
Assuntos
Antineoplásicos , Neoplasias de Mama Triplo Negativas , Humanos , Antineoplásicos/uso terapêutico , Perfilação da Expressão Gênica , Terapia de Alvo Molecular , Recidiva Local de Neoplasia/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/genética , FemininoRESUMO
OBJECTIVE: Our study aims to analyse and compare the efficacy, adverse effect profile and survival among the Paclitaxel/Cisplatin/5-Flurouracil (TPF) induction chemotherapy and Paclitaxel/carboplatin (PC) first line or cisplatin chemotherapy in a high-volume tertiary care cancer centre. MATERIALS AND METHODS: 215 patients with oral cavity cancer were recruited in this study. Patients with stages I-IIc underwent surgical resection or radiation therapy 66-74 GY/fraction. Patients of Stages III-IV were administered with either induction chemotherapy TPF or PC or cisplatin regimen. Treatment responses were assessed by CT and MRI. Response rates, survival and adverse effects data were tabulated and analysed. RESULTS: The mean age was 49.2 ± 11.68 years. Symptoms were ulceration (33.5%), growth (20.5%), pain (13%), ulcer-proliferative growth (8.4%) and swelling (13, 6%). The tumour site was found at the base of the tongue, C01 (42.2%) followed by C06 (35.8%), C08 (6.5%), C07 (5.2%) and C05 (4.6%). There were no significant differences ( P > 0.05) in efficacy and survival outcomes between the different groups of treatment. Median survival was achieved within 36 months. The major side effect observed were anaemia (15.81%), diarrhoea (36.2%), dyspepsia (28.8%), fever (33.95%), mucositis (28.85%), myalgia (33.95%) and nausea (7.9%). Survival among the responder categories (CR, PR and NR) was significantly different as per Log-rank analysis ( P = 0.015). CONCLUSIONS: TPF induction therapy and PC first line chemotherapy showed similar efficacy, safety profile and survival whereas cisplatin shows poor efficacy and safety and survival in Indian oral cancer patients.